Welcome to Eureka Street
Looking for thought provoking articles?Subscribe to Eureka Street and join the conversation.
Passwords must be at least 8 characters, contain upper and lower case letters, and a numeric value.
Eureka Street uses the Stripe payment gateway to process payments. The terms and conditions upon which Stripe processes payments and their privacy policy are available here.
Please note: The 40-day free-trial subscription is a limited time offer and expires 31/3/24. Subscribers will have 40 days of free access to Eureka Street content from the date they subscribe. You can cancel your subscription within that 40-day period without charge. After the 40-day free trial subscription period is over, you will be debited the $90 annual subscription amount. Our terms and conditions of membership still apply.
With the world clearly divided between those vaccinated against COVID-19 and those who are not, ethicists, public health specialists and politicians have become more preoccupied by the prospect of booster shots.
The stark differences between Australia and Papua New Guinea during this crisis are a reminder of how far we still have to go to make sure that all humans, no matter where they’re born, have access to decent healthcare.
The COVAX (COVID-19 Vaccines Global Access Facility) scheme, touted as a levelling measure against inequalities in vaccine access, is looking increasingly faulty. But one suggested mechanism to assist in achieving vaccine equity lies in the field of intellectual property rights.
As Australia deals with its own incursion of H1N1, a strange event on a Geneva-bound train reminds us that this virus is in human hands. Meanwhile the manufacture of a vaccine for the virus raises doubts about medical ethics and equity.